Search
Personalis Inc
PSNLAdd to Watchlist
13.527USD
-0.263-1.91%
Market hours （ET）Quotes delayed by 15 min
1.20BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-2.24%
5 Days
+18.67%
1 Month
+19.73%
6 Months
+69.36%
Year to Date
+69.36%
1 Year
+105.19%
Key Figures
13.970Open
14.240High
1.38MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.60%Turnover Ratio
13.790Prev. Close
13.234Low
12.23MTurnover
LossP/E Static
5.20P/B
0.00%Div Yield TTM
-31.92%ROA
14.18052wk High
0.50Volume Ratio
-81.28MNet Profit
88.75MShares
-1.0189EPS TTM
2.20Beta
-41.35%ROE
3.84052wk Low
7.87%Amplitude
1.82%Gross Margin
1.20BMarket Cap
4.48Reward/Risk
5.20%Risk Rate
TradingKey Stock Score of Personalis Inc
Currency: USD Updated: 2026-07-01Key Insights
Personalis Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 62 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.86.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Personalis Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Personalis Inc Highlights
StrengthsRisks
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Growing
The company is in a growing phase, with the latest annual income totaling USD 69.65M.
Undervalued
The company’s latest PE is -13.53, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 65.32M shares, increasing 2.84% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 5.33M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.43.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
10.857
Target Price
-18.98%
Upside Space
Personalis Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Personalis Inc Info
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Ticker SymbolPSNL
CompanyPersonalis Inc
CEOHall (Christopher M)
Websitehttps://www.personalis.com/
Related Instruments
+1.01%
+2.28%
+5.13%
+2.78%
+2.02%
+3.20%
+2.81%
+3.33%
+3.35%
+1.61%
+4.32%
+1.44%
+4.04%
+3.12%
+2.14%
0.00%
+2.90%
+3.31%
+0.39%
+4.40%Popular Instruments
52625.400
+371.100 (+0.71%)
29278.600
-520.700 (-1.75%)
7457.000
-18.500 (-0.25%)
14751.000
-604.000 (-3.93%)
67954.000
-1531.000 (-2.20%)
6349.500
+74.100 (+1.18%)
67.964
-0.004 (-0.01%)
307.300
+12.920 (+4.39%)
194.310
-3.270 (-1.66%)
4105.690
+74.920 (+1.86%)
FAQs
What is the current price of Personalis Inc (PSNL)?
The current price of Personalis Inc (PSNL) is 13.79.
What is the symbol of Personalis Inc?
The ticker symbol of Personalis Inc is PSNL.
What is the 52-week high of Personalis Inc?
The 52-week high of Personalis Inc is 14.07.
What is the 52-week low of Personalis Inc?
The 52-week low of Personalis Inc is 3.84.
What is the market capitalization of Personalis Inc?
The market capitalization of Personalis Inc is 1.44B.
Is Personalis Inc (PSNL) currently rated as Buy, Hold, or Sell?
According to analysts, Personalis Inc (PSNL) has an overall rating of Buy, with a price target of 10.86.
What is the Earnings Per Share (EPS TTM) of Personalis Inc (PSNL)?
The Earnings Per Share (EPS TTM) of Personalis Inc (PSNL) is -0.91.